The FDA has recorded an action on a supplement to biologics licence application BLA761420, held by Celltrion for AVTOZMA (tocilizumab-anoh), dated 2 September 2026.
What the entry does not say is what the supplement covers. Supplemental applications on an already-licensed biosimilar can concern manufacturing changes, a new presentation or device, labelling, or an added indication, and the database record identifies the application and the sponsor without distinguishing between them. So this is a change to an existing licence, not a new approval and not a safety communication — and it should not be reported to a patient as either.
The reason it is worth a rheumatologist's attention at all is supply. Tocilizumab now has several biosimilars in the US market, and the practical consequence of licence activity is usually which presentation a pharmacy stocks and at what price, rather than any change in how the drug is used. In India the regulatory position for this particular product is not stated in the FDA record and should not be inferred from it; tocilizumab itself is available here, and CDSCO decisions on individual biosimilars are separate. If a patient asks, the honest answer is that an American licensing change has no direct bearing on their supply.
- This is a supplement to an existing biosimilar licence, not a new approval
- The record does not state the subject of the supplement — do not describe it as an indication change
- No safety signal is implied by a supplemental approval
- Check with your pharmacy which tocilizumab product and presentation is actually stocked
- The Indian regulatory position for this product is not addressed by an FDA record
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free